loader

Ginkgo Bioworks Holdings Inc.

NYSE:DNA
1 min read

Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program

Ginkgo Datapoints and Apheris Launch Antibody Developability Consortium

Ginkgo Bioworks and the Ministry of Health of the Republic of Botswana Announce Plans to Develop and Implement New Biosecurity Capabilities in Botswana

Ginkgo Bioworks Launches Ginkgo Enzyme Services, Enabling Applications across Pharmaceuticals and Diagnostics, Food and Agriculture, and Beyond

Ginkgo Bioworks Provides Compensation Information Related to Recent Acquisitions

Ginkgo Announces Public Offering of Class A Common Stock

Ginkgo Bioworks Announces Proposed Public Offering of Class A Common Stock

Ginkgo Bioworks Reports Third Quarter 2022 Financial Results

Lygos and Ginkgo Bioworks Announce Partnership to Optimize Production of Biobased Specialty Chemicals

Ginkgo Bioworks To Present New Data on High Throughput Pooled Screening Method to Discover Novel CAR-T Designs for Solid Tumors

Ginkgo Bioworks Holdings Inc is building a platform to enable customers to program cells as easily to program computers. The company's platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals.

Latest News

More News

Latest News

Outlook Reports world

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES